Haifa-based Pluristem Therapeutics Ltd. announced last week that four of six Israeli Covid-19 patients treated for a week or more with its PLX stem cells were showing signs of improvement. All the patients in question were on ventilators and were suffering from acute respiratory failure and inflammatory complications associated with Covid-19. Four of the patients also demonstrated failure of other organ systems, including cardiovascular and kidney failure, indicating critical disease and poor prognosis. The rate of recovery among patients in this condition up to now has been around 50%.
